The Wrabetz Laboratory was interested in the molecular genetics of myelination, studied primarily in transgenic mice. They focused on the pathogenesis of inherited demyelinating neuropathies, and they developed and characterized multiple mouse models of Charcot-Marie-Tooth (CMT) neuropathies.
The laboratory closed in July 2022 when Dr. Wrabetz retired.
The Wrabetz Laboratory was interested in the molecular genetics of myelination, studied primarily in transgenic mice. They focused on the pathogenesis of inherited demyelinating neuropathies, and developed and characterized multiple mouse models of Charcot-Marie-Tooth (CMT) neuropathies. By introducing authentic CMT mutations from patients into these mice, they were revealing the mechanisms of disease, potential avenues of therapy and the opportunity to test resulting medicines in preclinical trials for CMT. Dr. Wrabetz's laboratory translated this experience into the generation of new mouse models of Krabbe disease that carry authentic GalC mutations found in patients with diverse clinical phenotypes. These animal models will provide insight into the effect of different mutations on the function of the galactosylceramidase protein and on the pathogenesis of the disease. Dr. Wrabetz's work was supported by the National Institutes of Health; Telethon, Italy; the European Community, the Italian and Great Britain Multiple Sclerosis Societies, the Mariani Foundation, the Cariplo Foundation, SUNY Brain Network of Excellence, and the Charcot-Marie-Tooth Association.
Lawrence Wrabetz M.D. was the Founding Director of the Institute for Myelin and Glia Exploration and Professor in Neurology and Biochemistry in the Jacobs School of Medicine and Biomedical Sciences, University at Buffalo.